BioUtah will represent Utah's life sciences industry at the prestigious J.P. Morgan 43rd Annual Healthcare Conference, demonstrating the state's growing prominence in medical innovation and entrepreneurship. Led by President and CEO Kelvyn Cullimore, the organization will showcase Utah's strengths in medical device manufacturing, biotechnology, pharmaceuticals, and digital health.
The conference presents a critical opportunity to highlight Utah's rapidly expanding life sciences ecosystem. According to a University of Utah Kem C. Gardner Policy Institute study, the state consistently ranks among the top three states for life sciences growth, underlining its significant economic and technological potential.
Utah's life sciences sector contributes substantially to the state's economy, generating $22.6 billion in GDP and supporting approximately 180,000 jobs. The industry's success stems from a collaborative environment that includes business, university, and government partnerships, creating a fertile ground for innovation and startup development.
During the conference, BioUtah will co-host a networking reception and facilitate connections between Utah stakeholders, investors, and industry leaders. Multiple Utah-based life sciences companies developing cutting-edge medical technologies are expected to present their innovations.
The organization will also promote its upcoming Entrepreneur and Investor Life Sciences Summit, which will further highlight Utah's commitment to fostering medical and technological advancements. This event, presented in partnership with the University of Utah's Technology Licensing Office, will bring together entrepreneurs, investors, and industry experts.
The J.P. Morgan Healthcare Conference, recognized as the largest investment symposium in the industry, provides an ideal platform for BioUtah to demonstrate the state's potential and attract further investment in its burgeoning life sciences sector.
